Drug developer Cennerv makes second bid to list on Catalist
Singapore
SINGAPORE-based biotech Cennerv Pharmaceuticals is making a second attempt at an initial public offering (IPO) on the Singapore Exchange's Catalist board, with the lodging of another preliminary offer document on Wednesday. Details of the pricing, amount to be raised, and timing of the offer have yet to be announced.
The firm, which develops drugs to treat central nervous system disorders, first registered a preliminary offer document for a planned listing in September last year. Asked why this was subsequently withdrawn, the company said: "Due to adverse market conditions in the last quarter of 2018, the company decided not to proceed with a listing in 2018."
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Amazon’s AWS commits extra S$12 billion to boost Singapore cloud infrastructure
New Thai finance chief wants monetary, fiscal policies aligned
Swiss-Asia Financial Services fined S$2.5 million for money-laundering rule breaches
Singapore-based Princeton Digital gets green loan for US$1.5 billion Asia AI hub
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Apple is working on its own AI chip for data centres: WSJ